Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: RobbRacer who wrote (20841)	3/15/1999 9:48:00 PM
From: Anthony@Pacific	Read Replies (2) \| Respond to of 122087

ITs bullsh1t news...any pain will be short lived ENMD is a scam and BM knew it and bailed ...they have no funding they cant get anywher beside many other companies are much farther along in clinical studies using these compounsds.....look at this story below:: Story 1 / 20: 99 <GO> for list of story options. Equity C N Page 1 of 5 BN Boston Life Compound Halts Growth of Spreading Tumors in Mice Mar 15 1999 14:30 Boston Life Compound Halts Growth of Spreading Tumors in Mice Washington, March 15 (Bloomberg) -- Boston Life Sciences Inc.'s experimental drug halted the growth of metastatic tumors in the lungs of mice, according to a new study. Researchers found that twice-a-week doses of the compound, a protein called Troponin I, were effective against cancer that had metastasized, or spread, and begun to form tumors in the lungs of the mice in the study. The study was released after the close of trading on U.S. markets and appears in tomorrow's edition of the Proceedings of the National Academy of Sciences. Earlier, shares in Boston Life Sciences rose 1 1/8 to an all time high of 9 9/16. ''This is the first time that the discovery and scientific work on Troponin is appearing in a prestigious, peer-reviewed journal,'' said Marc Lanser, chief scientific officer and founder of Boston Life Sciences. ''It's no longer taking our word for it; this is now a documented case.'' There is no guarantee the mouse findings will hold true in humans as well. Still, the research is encouraging, Lanser said. Story 1 / 20: 99 <GO> for list of story options. Equity C N Page 2 of 5 The schedule of twice-weekly doses, so far effective only in mice, could prove practical and convenient for patients and cut costs, he said. ''We have more or less narrowed it down to twice a week, a relatively small dose and quite infrequent in regards to what has been reported'' with similar agents, Lanser said. ''That is the most exciting thing to come out of this work.'' Officials said the company plans to start human trials of the compound later this year. Anti-Angiogenesis Earlier animal research has already indicated Troponin I can slow tumors by strangling their blood supply -- a process called anti-angiogenesis. In the study released today, a team of Boston doctors showed that the compound is effective against metastatic tumors which grew in the lungs of mice after the mice were given intravenous injections of a kind of skin cancer called melanoma. Most major cancers are made up of solid tumors, which require blood and oxygen to survive. Blood vessels often grow into the tumor, and play a role in spreading the disease. Blocking this blood vessel supply is the aim of anti-angiogenesis treatments. Story 1 / 20: 99 <GO> for list of story options. Equity C N Page 3 of 5 Boston Life Sciences is one of a group of companies, including EntreMed Inc. and Agouron Pharmaceuticals Inc., racing to develop cancer treatments based on blocking angiogenesis. Shares in tiny Rockville, Maryland-based EntreMed more than quadrupled in May after a New York Times feature story touted the anti-cancer potential for two of the company's compounds. Shares fell over the following months, and the compounds -- called angiostatin and endostatin -- are in final stage animal studies now. Most of the most powerful anti-angiogenesis drugs are still in the animal stage of testing and there is no proof that what helps mice will also prove effective in humans. Why It Works Separately today in the Proceedings of the National Academy of Science, Duke University researchers presented a study explaining why one well known angiogenesis blocker has the effect it does. Angiostatin, under development at EntreMed, latches onto and inactivates an enzyme which supplies the energy needed for vessel growth, the Duke team said. Story 1 / 20: 99 <GO> for list of story options. Equity C N Page 4 of 5 --Kristin Reed in Washington (202) 624-1858 /mfr Story illustration: For a chart of the recent stock price movement in Boston Sciences' shares, type BLSI US <Equity> GP. Company news: Industry news: BLSI US <Equity> CN NI BTC Biotechnology TCLN US <Equity> CN NI DRG Drug news ENMD US <Equity> CN AGPH US <Equity> CN BQ, DES, CH1 Regional news: News by category: NI TX Texas NI FDA FDA NI MA Massachusetts NI MEDICAL Medical studies NI CA California NI HEA Health news NI SCIENCE Science news People: For more on any of the people in this story, type WHO followed by the person's first and last name and <Go>. For more stories about biotechnology companies and the FDA, type